Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore

International Journal of Clinical Pharmacy

Volumn 38, Issue 5, 2016, Pages 1230-1240

  Chua, Wen Bing Brandon ^a   Cheen, Hua Heng Mcvin ^b,c   Kong, Ming Chai ^b   Chen, Li Li ^b   Wee, Hwee Lin ^c  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticoagulation; Atrial fibrillation; Cost effectiveness; Pharmacist; Singapore; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; MARKOV CHAIN; PHARMACEUTICAL CARE; PHARMACIST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SINGAPORE; AGED; BLOOD CLOTTING; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMIC MODEL; ECONOMICS; FEMALE; HUMAN; MALE; PROCEDURES; PROFESSIONAL STANDARD;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MODELS, ECONOMIC; PHARMACISTS; PROFESSIONAL ROLE; SINGAPORE;

EID: 84979683956     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-016-0357-7     Document Type: Article

References (37)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469–73.
2. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol. 2015;180:246–54.
3. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24:1021–33.
4. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891–6.
5. National Registry of Diseases Office: Latest publications. www.nrdo.gov.sg. Accessed 15 February 2015.
6. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.
7. Department of Statistics Singapore. Latest data. http://www.singstat.gov.sg/statistics/latest-data. Accessed 5 Dec 2014.
8. The World Bank. Price level ratio of PPP conversion factor (GDP) to market exchange rate. http://data.worldbank.org/indicator/PA.NUS.PPPC.RF. Accessed 7 April 2016.
9. World Health Organization. World Health Statistics 2015. http://www.who.int/gho/publications/world_health_statistics/2015/en/. Accessed 7 April 2016.
10. Goto S, Zhu J, Liu L, Oh B-H, Wojdyla DM, Aylward P, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J. 2014;168:303–9.
11. Wong KSL, Hu DY, Oomman A, Tan R-S, Patel MR, Singer DE, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. 2014;45:1739–47.
12. Department of Statistics Singapore: publications and papers. www.singstat.gov.sg/publications/publications-and-papers/population. Accessed 7 Oct 2014.
13. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007;28:2346–53.
14. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.
15. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54:1231–6.
16. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1–11.
17. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
18. van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health. 2012;15:708–15.
19. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73–83.
20. Kang EJ, Ko SK. A catalogue of EQ-5D utility weights for chronic diseases among noninstitutionalized community residents in Korea. Value Health. 2009;12(Suppl 3):S114–7.
21. Abdin E, Subramaniam M, Vaingankar JA, Luo N, Chong SA. Measuring health-related quality of life among adults in Singapore: population norms for the EQ-5D. Qual Life Res. 2013;22:2983–91.
22. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968–77.
23. You JH, Chan FW, Wong RS, Cheng G. Cost-effectiveness of two models of management for patients on chronic warfarin therapy—a Markov model analysis. Thromb Haemost. 2003;90:1106–11.
24. Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A, Jeanpeerapong N. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. Thromb Res. 2013;132:437–43.
25. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990–2010: findings from the global burden of disease study 2010. Lancet. 2014;383:245–54.
26. Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 2007;78:836–40.
27. Poon MT, Fonville AF. Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85:660–7.
28. Organisation for Economic Co-operation and Development/World Health Organization. Health at a Glance: Asia-Pacific. www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-asia-pacific-2014_health_glance_ap-2014-en. Accessed 29 Mar 2015.
29. Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113:662–8.
30. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700–5.
31. Toyoda K, Okada Y, Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study. Cerebrovasc Dis. 2007;24:289–95.
32. Yokota C, Minematsu K, Hasegawa Y, Yamaguchi T. Long-term prognosis, by stroke subtypes, after a first-ever stroke: a hospital-based study over a 20-year period. Cerebrovasc Dis. 2004;18:111–6.
33. Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77:439–46.
34. Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5:532–40.
35. Ministry of Health Singapore: Hospital bill size. www.moh.gov.sg/content/moh_web/home/costs_and_financing/HospitalBillSize.html. Accessed 30 Jan 2015.
36. Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2418–27.
37. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186.